Reprogenetics and pharmacogenetics: In whose best interests? Read more about Reprogenetics and pharmacogenetics: In whose best interests?
Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics report Read more about Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics report
Pharmacogenetics and ethnically targeted therapies: The new drug BiDil marks the return of biology to the debate about race and ethnicity Read more about Pharmacogenetics and ethnically targeted therapies: The new drug BiDil marks the return of biology to the debate about race and ethnicity
Pharmacogenetics and ethnically targeted therapies: Racial drugs need to be put in context; authors' reply Read more about Pharmacogenetics and ethnically targeted therapies: Racial drugs need to be put in context; authors' reply
The molecularization of race: Institutionalizing human difference in pharmacogenetics practice Read more about The molecularization of race: Institutionalizing human difference in pharmacogenetics practice
Pharmacogenetics and ethical considerations: Why care? Read more about Pharmacogenetics and ethical considerations: Why care?
Education, ethics and knowledge deficits in clinical pharmacogenetics Read more about Education, ethics and knowledge deficits in clinical pharmacogenetics
Lay perspective on pharmacogenetics and its application to future drug treatment: A Danish quantitative survey Read more about Lay perspective on pharmacogenetics and its application to future drug treatment: A Danish quantitative survey
Pharmacogenetics: A new challenge for health law Read more about Pharmacogenetics: A new challenge for health law
The diffusion of innovation: Factors influencing the uptake of pharmacogenetics Read more about The diffusion of innovation: Factors influencing the uptake of pharmacogenetics
